Oramed initiates Phase 3 oral insulin trials


Oramed Pharmaceuticals (NASDAQ, TASE:ORMP) began screening patients for its two Phase 3 trials evaluating ORMD-0801 for the treatment of Type 2 diabetes.

The trials will enroll a total of 1,125 Type 2 diabetes patients who have inadequate glycemic control. Patients will be treated over a period of six-to-12 months, with efficacy data expected after all patients have completed the first six-month treatment period.

The first of the two Phase 3 trials, ORA-D-013-1, is recruiting 675 patients who are currently on up to three oral glucose-lowering agents. The study’s primary endpoint is the efficacy of ORMD-0801 in improving glycemic control as assessed by A1c, compared with placebo. The secondary endpoint is the change from baseline in fasting plasma glucose at 26 weeks.

In a statement, Oramed’s CEO, Nadav Kidron, said, “ORMD-0801 is the first oral insulin capsule to achieve the requisite efficacy and safety data enabling us to run the world’s first [FDA-approved] Phase 3 oral insulin trial. Oramed is proud to lead the field in reaching this very significant diabetes treatment milestone.”

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.